Fine-tuning signal strength in CD5 CAR-NK cells for targeted T cell cancer therapy
Optimized modulation of scFv and CAR expression is crucial for designing a CAR that achieves high anti-cancer efficacy and is safe in normal cells. Our results suggest a promising avenue for optimized CD5 CAR-NK cell therapy to manage T cell malignancies while minimizing off-tumor effects.
Authors
- Myeongjin Choi (ORCID: https://orcid.org/0000-0001-8891-8286)
- Yu Bin Lee (ORCID: https://orcid.org/0000-0002-1470-6499)
- Tae‐Don Kim (ORCID: https://orcid.org/0000-0002-5910-4264)
- So-Ra Park
- Yu Jung Kim (ORCID: https://orcid.org/0000-0002-5037-0523)
- Soo Yun Lee
- Kyoung‐Sik Moon (ORCID: https://orcid.org/0000-0003-3443-8230)
- Seona Jo
- Seong‐Yun Jeong (ORCID: https://orcid.org/0000-0003-0959-5488)
- Seok‐min Kim (ORCID: https://orcid.org/0000-0002-1609-6786)
- Sunyoung Lee (ORCID: https://orcid.org/0000-0002-6893-3136)
- Ji Hyun Kim (ORCID: https://orcid.org/0000-0002-1967-4772)
- Yoonji Kim (ORCID: https://orcid.org/0000-0003-0690-2745)
- Mi-lang Kyun
Institutions
- Korea Institute of Toxicology (KR)
- Osong Medical Innovation Foundation (KR)
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Sungkyunkwan University (KR)
- Korea University of Science and Technology (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1674376
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Korea Institute of Toxicology
- National Research Foundation of Korea
- Korea Drug Development Fund